SynthesisBrain and behavior2026
Factors Associated With Antiseizure Medication Adherence in Patients With Epilepsy: A Systematic Review.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpilepsy is one of the most common chronic neurological disorders worldwide, and adherence to antiseizure medication (ASM) therapy is essential for seizure control and improved quality of life. Poor adherence has been associated with increased morbidity, mortality, and healthcare burden. This systematic review aimed to examine factors associated with ASM adherence among patients with epilepsy across different sociocultural and clinical settings.
methodsSystematic searches were conducted in PubMed, Scopus, Web of Science, and Google Scholar databases. A total of 5736 records were identified and screened according to the PRISMA 2020 guidelines. After applying predefined eligibility criteria and assessing methodological quality using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists, 41 quantitative studies were included in the final synthesis.
resultsMost studies reported moderate levels of ASM adherence. Factors associated with nonadherence were categorized according to the five World Health Organization (WHO) dimensions of adherence. The most frequently reported barriers included forgetfulness, complex medication regimens (particularly polytherapy), and adverse drug effects. Psychosocial factors such as depression, anxiety, negative medication beliefs, and perceived stigma were consistently associated with lower adherence. In addition, socioeconomic barriers including low income and high medication costs were frequently associated with poor adherence, particularly in low- and middle-income countries.
conclusionASM adherence in epilepsy is associated with a complex interaction of biological, psychosocial, cultural, and economic factors. Major barriers include forgetfulness, treatment complexity, adverse effects, mental health problems, stigma, and financial difficulties. Improving adherence may require multidimensional interventions, including individualized patient education, psychosocial support, simplified treatment regimens, and strengthened healthcare policies targeting both patient- and system-level barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.